TY - JOUR
T1 - Biomimetic gold nanocomplexes for gene knockdown
T2 - Will gold deliver dividends for small interfering RNA nanomedicines?
AU - Guo, Jianfeng
AU - Rahme, Kamil
AU - Fitzgerald, Kathleen A.
AU - Holmes, Justin D.
AU - O’Driscoll, Caitriona M.
N1 - Publisher Copyright:
© 2015, Tsinghua University Press and Springer-Verlag Berlin Heidelberg.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - RNA interference (RNAi) effectors such as small interfering RNA (siRNA) and micro RNA (miRNA) can selectively downregulate any gene implicated in the pathology of a disease. Therefore, RNAi-based therapies have immense potential for the treatment of a wide range of diseases. However, pharmacokinetic and pharmacodynamic studies have revealed that these therapeutic agents have poor bioactivity due to a number of factors, including insufficient plasma drug levels, short plasma half-lives, renal clearance, and hepatic metabolism. Non-viral delivery may facilitate the clinical application of siRNA-based therapeutics by helping to overcome these barriers. Recently, the potential of gold nanoparticles (AuNPs) as multifunctional carriers for transporting drugs, proteins, and genetic materials has been demonstrated. In this review, some of the key properties of AuNPs relevant to siRNA delivery, such as physical properties and surface chemistry have been described. In addition, the ability of AuNP-based formulation strategies to successfully overcome delivery barriers associated with siRNA, and the potential for this material to translate into safe and effective nanomedicines are critically discussed. [Figure not available: see fulltext.]
AB - RNA interference (RNAi) effectors such as small interfering RNA (siRNA) and micro RNA (miRNA) can selectively downregulate any gene implicated in the pathology of a disease. Therefore, RNAi-based therapies have immense potential for the treatment of a wide range of diseases. However, pharmacokinetic and pharmacodynamic studies have revealed that these therapeutic agents have poor bioactivity due to a number of factors, including insufficient plasma drug levels, short plasma half-lives, renal clearance, and hepatic metabolism. Non-viral delivery may facilitate the clinical application of siRNA-based therapeutics by helping to overcome these barriers. Recently, the potential of gold nanoparticles (AuNPs) as multifunctional carriers for transporting drugs, proteins, and genetic materials has been demonstrated. In this review, some of the key properties of AuNPs relevant to siRNA delivery, such as physical properties and surface chemistry have been described. In addition, the ability of AuNP-based formulation strategies to successfully overcome delivery barriers associated with siRNA, and the potential for this material to translate into safe and effective nanomedicines are critically discussed. [Figure not available: see fulltext.]
KW - multifunctional nanoparticles
KW - nanotoxicity of gold nanoparticles
KW - RNA interference (RNAi)-based therapeutics
KW - siRNA delivery
UR - https://www.scopus.com/pages/publications/84943364330
U2 - 10.1007/s12274-015-0829-4
DO - 10.1007/s12274-015-0829-4
M3 - Review article
AN - SCOPUS:84943364330
SN - 1998-0124
VL - 8
SP - 3111
EP - 3140
JO - Nano Research
JF - Nano Research
IS - 10
ER -